After Dr Reddy's, Sun Pharma Commits To Not Selling Semaglutide In India till 2026

The Delhi High Court on Wednesday recorded Sun Pharmaceutical Industries Ltd.'s assurance that it will not sell its semaglutide-based drug in India until March 20, 2026, when Danish drugmaker Novo Nordisk's patent expires.

Appearing before Justice Manmeet Pritam Singh Arora, the company also committed to exporting the drug only to countries where Novo does not hold patent rights. Subsequently, it allowed Sun Pharma to export its semaglutide preparations outside the country. 

This development comes just days after Dr. Reddy's Laboratories and OneSource Specialty Pharma gave similar undertakings in another semaglutide dispute. Semaglutide is the active ingredient in Novo Nordisk's widely used diabetes and weight-loss medications Ozempic and Wegovy.

In that earlier case, through an order on December 2, the High Court declined to grant Novo interim relief, holding that the Indian companies had raised a strong and credible challenge to the validity of Novo's patent. Their existing commitments not to sell semaglutide in India were allowed to continue, with permission only to export the drug to countries where Novo lacks patent protection.

In Sun Pharma's case, the Court directed the company to file an affidavit restating its undertaking and to place on record details of its export accounts.

Sun Pharma also stated that if the December 2 ruling is appealed and any variation favours Dr. Reddy's, it would seek to rely on that determination in the same manner.